281 completed, 115 recruiting, 84 unknown, 71 terminated. 266 Phase 2, 190 Phase 1, 71 Not applicable, 58 Phase 3, 27 Phase 4.
Follow Acute Lymphoblastic Leukemia: new trials by email Literature Review of Acute Lymphoblastic Leukemia trials Research Report on Acute Lymphoblastic Leukemia
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| 2 Gy Total Body Irradiation As Part Of Conditioning Treatment For Patients With Acute Lymphoblastic Leukemia Undergoing CAR T Cell Therapy CAR T cell therapy - Acute Lymphoblastic Leukemia | Not applicable | Not yet recruiting | M.D. Anderson Cancer Center | 20 | 2027-03-01 | 2026-10-05 |
| huCART19-IL18-CD428z Cells for the Treatment of Patients With HIV With CD19+ Cancers huCART19-IL18-CD428z cells - Non-Hodgkin Lymphoma, Chronic Lymphocytic Leukemia | Phase 1 | Not yet recruiting | University of Pennsylvania | 6 | 2027-01-01 | 2026-10-26 |
| Depletion of CD45RA Positive Naive T Cells for the Prevention of Graft Versus Host Disease in Older Patients Undergoing Allogeneic Hematopoietic Cell Transplantation for Acute Leukemia or Myelodysplastic Syndrome Allogeneic CD34+-enriched and CD45RA-depleted PBSCs, Biospecimen Collection, Bone Marrow Aspiration - Acute Biphenotypic Leukemia, Acute Leukemia | Phase 2 | Not yet recruiting | Fred Hutchinson Cancer Center | 52 | 2027-01-01 | 2026-09-14 |
| Prevention of Oral Mucositis in Adults in With Hematologic Malignancy Aloe Vera Mouthwash, Standard of Care - Acute Leukemia, Acute Myeloid Leukemia | Not applicable | Not yet recruiting | Wake Forest University Health Sciences | 206 | 2027-01-01 | 2026-10-22 |
| A Study of Sonrotoclax (BGB-11417) in Children With Relapsed or Refractory Acute Myeloid Leukemia and B-cell Acute Lymphoblastic Leukemia sonrotoclax, Azacitidine, Inotuzumab ozogamicin - Relapsed Acute Myeloid Leukemia, Refractory Acute Myeloid Leukemia | Phase 1 / Phase 2 | Not yet recruiting | BeOne Medicines | 30 | 2026-12-01 | 2026-10-26 |
| Study to Characterize Mismatched to Fully HLA-Matched Ossium HPC, Marrow and Living Donor Transplantation in Patients With Hematologic Malignancies Ossium HPC, Marrow, Standard of care living donor - Haplo Related, Standard of care living donor - Mismatched Unrelated - Hematologic Malignancy, Acute Leukemia | Not applicable | Not yet recruiting | Ossium Health, Inc. | 300 | 2026-12-01 | 2026-09-10 |
| Digital Patient-Reported Assessment in Older Adults With Acute Leukemia Digital Patient-Reported Assessment Pathway - Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia | Not applicable | Not yet recruiting | Fundación para la Investigación Biosanitaria del Principado de Asturias | 20 | 2026-12-01 | 2026-10-07 |
| Anti-CRLF2-R/TSLPR Chimeric Antigen Receptor T Cells (TSLPR-CART) in Participants With Recurrent or Refractory CRLF2-R/TSLPR-Overexpressing B-Cell Acute Lymphoblastic Leukemia (B-ALL) TSLPR-CART, Cyclophosphamide, Fludarabine - B-All, Acute Lymphoblastic Leukemia | Phase 1 | Recruiting | National Cancer Institute (NCI) | 57 | 2026-11-04 | 2026-10-30 |
| A Multicenter Study to Evaluate Next-Generation Sequencing (NGS) Testing and Monitoring of B-Cell Recovery to Guide Management Following Chimeric Antigen Receptor T-cell (CART) Induced Remission in Children and Young Adults With B Lineage Acute Lymph... NGS testing - B-All, Acute Lymphoblastic Leukemia | Not applicable | Recruiting | National Cancer Institute (NCI) | 60 | 2026-11-04 | 2026-10-30 |
| HEM-iSMART E: Capivasertib + Venetoclax + Dexamethasone in Pediatric Patients With Relapsed or Refractory Hematological Malignancies Capivasertib, Venetoclax, Dexamethasone - Acute Lymphoblastic Leukemia, Lymphoblastic Lymphoma (Precursor B-Lymphoblastic Lymphoma/Leukaemia) Recurrent | Phase 1 / Phase 2 | Not yet recruiting | Princess Maxima Center for Pediatric Oncology | 42 | 2026-10-01 | 2025-09-16 |
| A Study to Find the Highest Dose of SNDX-5613 (Revumenib) as a Treatment Option After Hematopoietic Stem Cell Transplant in Children With Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia, and Mixed Phenotype Acute Leukemia Biospecimen Collection, Bone Marrow Aspiration, Bone Marrow Biopsy - Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia | Phase 1 | Withdrawn | Children's Oncology Group | 2026-09-10 | 2026-05-05 | |
| A Vaccine (CMV-MVA Triplex Vaccine) for the Enhancement of CMV-Specific Immunity and the Prevention of CMV Viremia in Patients Undergoing Haploidentical Hematopoietic Stem Cell Transplant Biospecimen Collection, Electronic Health Record Review, Haploidentical Hematopoietic Cell Transplantation - Accelerated Phase Chronic Myeloid Leukemia, BCR-ABL1 Positive, Acute Lymphoblastic Leukemia | Phase 1 | Recruiting | City of Hope Medical Center | 46 | 2026-09-09 | 2026-10-23 |
| CAR-T Treatment in Pediatric and Adult Acute Lymphoblastic Leukemia Acute Lymphoblastic Leukemia, B-Cell Acute Lymphoblastic Leukaemia | Not yet recruiting | Gruppo Italiano Malattie EMatologiche dell'Adulto | 107 | 2026-09-01 | 2026-06-03 | |
| A Single-center, Prospective, Exploratory Clinical Study Lisaftoclax - Acute Lymphoblastic Leukemia | Not applicable | Not yet recruiting | LanZhou University | 30 | 2026-08-01 | 2026-08-31 |
| Plasma ctDNA Monitoring in Pediatric Acute Leukemia Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia | Not yet recruiting | Institute of Hematology & Blood Diseases Hospital, China | 25 | 2026-07-11 | 2026-08-07 | |
| Safety and Efficacy of Asciminib in Pediatrics and Young Adults With Relapse/Refractory (r/r) Philadelphia Positive (Ph+) or ABL-class Ph-like Acute Lymphoblastic Leukemia (ALL) Asciminib Adult formulation, Asciminib Pediatric formulation, Dexamethasone - Acute Lymphoblastic Leukemia, Leukemia, Lymphoblastic, Acute, Philadelphia-Positive | Phase 1 / Phase 2 | Recruiting | Novartis Pharmaceuticals | 50 | 2026-07-05 | 2026-10-15 |
| CD22 CAR T-cells to Extend Remission Following Commercial CD19 CAR T-cells in Children, Adolescents, and Adults With Relapsed/Refractory B-cell Acute Lymphoblastic Leukemia CD22 CAR-transduced T cells, Cyclophosphamide, Fludarabine - Acute Lymphoblastic Leukemia, B-All | Phase 2 | Recruiting | National Cancer Institute (NCI) | 20 | 2026-06-16 | 2026-10-26 |
| Whole Genome Sequencing (ChromoSeq®) for Acute Lymphoblastic Leukemia (ALL) Patients Acute Lymphoblastic Leukemia | Recruiting | Washington University School of Medicine | 60 | 2026-06-03 | 2026-10-09 | |
| Phase I Study of FXS0683 in the Treatment of Blood Tumors FXS0683 - B-Cell Lymphoma, Acute Myeloid Leukemia | Phase 1 | Recruiting | Shanghai Fosun Pharmaceutical Industrial Development Co. Ltd. | 228 | 2026-06-02 | 2026-10-14 |
| SHR2554/AZA + Overlapped Modified BUCY for High-risk/Relapsed Leukemia/MDS SHR2554/AZA + Overlapped mBUCY, mBUCY conditioning Regimen Group - Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia | Phase 2 | Not yet recruiting | The First Affiliated Hospital of Soochow University | 180 | 2026-06-01 | 2026-06-10 |
Showing 20 of 663. Sign in to see all of them.
Precursor Cell Lymphoblastic Leukemia-Lymphoma (663) · Leukemia, Myeloid, Acute (219) · Myelodysplastic Syndromes (134) · Lymphoma, Non-Hodgkin (105) · Leukemia, Myelogenous, Chronic, BCR-ABL Positive (97) · Leukemia (88) · Hodgkin Disease (63) · Leukemia, Lymphocytic, Chronic, B-Cell (58) · Lymphoma (46) · Multiple Myeloma (45) · Burkitt Lymphoma (44) · Leukemia, Biphenotypic, Acute (43) · Hematologic Neoplasms (39) · Neoplasms (38) · Myeloproliferative Disorders (32)
Hemic and Lymphatic Diseases (663) · Neoplasms by Histologic Type (659) · Lymphatic Diseases (658) · Immune System Diseases (657) · Immunoproliferative Disorders (655) · Leukemia, Lymphoid (655) · Hematologic Diseases (654) · Lymphoproliferative Disorders (654) · Neoplasms (625) · Leukemia (575) · Leukemia, Myeloid (233) · Pathological Conditions, Signs and Symptoms (206) · Pathologic Processes (195) · Bone Marrow Diseases (172) · Disease Attributes (159)
Cyclophosphamide (119) · Methotrexate (80) · Cytarabine (75) · Vincristine (68) · Dexamethasone (64) · fludarabine (56) · Mercaptopurine (44) · pegaspargase (41) · Doxorubicin (35) · Whole-Body Irradiation (34) · fludarabine phosphate (31) · Prednisone (30) · blinatumomab (30) · Calcium Dobesilate (29) · Daunorubicin (27)
St. Jude Children's Research Hospital (38) · M.D. Anderson Cancer Center (24) · Children's Oncology Group (18) · City of Hope Medical Center (18) · National Cancer Institute (NCI) (18) · Fred Hutchinson Cancer Center (16) · PETHEMA Foundation (14) · Dana-Farber Cancer Institute (13) · Novartis Pharmaceuticals (13) · Masonic Cancer Center, University of Minnesota (11) · Memorial Sloan Kettering Cancer Center (11) · Gruppo Italiano Malattie EMatologiche dell'Adulto (9) · Assistance Publique - Hôpitaux de Paris (8) · The First Affiliated Hospital of Soochow University (8) · Aarhus University Hospital (7)
United States (360) · China (74) · Italy (50) · Canada (45) · France (42) · Germany (39) · Spain (36) · Denmark (29) · United Kingdom (27) · Australia (24) · Netherlands (21) · Sweden (16) · Belgium (15) · Israel (15) · Mexico (14)
Sima Jeha, MD (7) · Elias Jabbour (6) · Kjeld Schmiegelow, M.D. (6) · Wendy Stock, MD (4) · Brenda Sandmaier (3) · Denis Claude Roy, Prof MD (3) · Heng Mei, M.D., Ph.D (3) · Jae Park, MD (3)
PMID 41671463, PMID 35622074, PMID 39121442, PMID 37890117, PMID 40195173, PMID 24970932, PMID 26590194, PMID 27209293, PMID 27873237, PMID 29284596, PMID 33026184, PMID 33242441, PMID 33741715, PMID 34267079, PMID 34687939, PMID 35799791, PMID 37486616, PMID 38446568, PMID 38551807, PMID 40315406, PMID 10339508, PMID 10577848, PMID 11401921, PMID 11675328, PMID 11753612, PMID 11882484, PMID 11986239, PMID 11986774, PMID 12204832, PMID 12296514, PMID 12370753, PMID 12393746, PMID 12415113, PMID 12508246, PMID 12526921, PMID 12571459, PMID 12661004, PMID 12756163, PMID 12951583, PMID 14712141, PMID 14978794, PMID 15020610, PMID 15026336, PMID 15124687, PMID 15128601, PMID 15197203, PMID 15226337, PMID 15247354, PMID 15280635, PMID 15298960
P30CA033572 (14), P30CA015704 (10), U10CA098543 (9), U10CA180886 (7), UG1CA189955 (5), 2016 (4), 2018 (4), P01CA078902 (4), 2005 (3), P01CA018029 (3), 2017 (2), 2023 (2), 2025 (2), U10CA095861 (2), U10CA180888 (2)